Show simple item record

dc.contributor.authorGbala, Ifeoluwa D
dc.contributor.authorMacharia, Rosaline W
dc.contributor.authorBargul, Joel L
dc.contributor.authorMagoma, Gabriel
dc.date.accessioned2022-10-11T08:34:03Z
dc.date.available2022-10-11T08:34:03Z
dc.date.issued2022
dc.identifier.citationGbala ID, Macharia RW, Bargul JL, Magoma G. Membrane Permeabilization and Antimicrobial Activity of Recombinant Defensin-d2 and Actifensin against Multidrug-Resistant Pseudomonas aeruginosa and Candida albicans. Molecules. 2022 Jul 6;27(14):4325. doi: 10.3390/molecules27144325. PMID: 35889198; PMCID: PMC9317813.en_US
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/35889198/
dc.identifier.urihttp://erepository.uonbi.ac.ke/handle/11295/161417
dc.description.abstractAntimicrobial resistance requires urgent efforts towards the discovery of active antimicrobials, and the development of strategies to sustainably produce them. Defensin and defensin-like antimicrobial peptides (AMPs) are increasingly gaining pharmacological interest because of their potency against pathogens. In this study, we expressed two AMPs: defensin-d2 derived from spinach, and defensin-like actifensin from Actinomyces ruminicola. Recombinant pTXB1 plasmids carrying the target genes encoding defensin-d2 and actifensin were generated by the MEGAWHOP cloning strategy. Each AMP was first expressed as a fusion protein in Escherichia coli, purified by affinity chromatography, and was thereafter assayed for antimicrobial activity against multidrug-resistant (MDR) pathogens. Approximately 985 µg/mL and 2895 µg/mL of recombinant defensin-d2 and actifensin, respectively, were recovered with high purity. An analysis by MALDI-TOF MS showed distinct peaks corresponding to molecular weights of approximately 4.1 kDa for actifensin and 5.8 kDa for defensin-d2. An in vitro antimicrobial assay showed that MDR Pseudomonas aeruginosa and Candida albicans were inhibited at minimum concentrations of 7.5 µg/mL and 23 µg/mL for recombinant defensin-d2 and actifensin, respectively. The inhibitory kinetics of the peptides revealed cidal activity within 4 h of the contact time. Furthermore, both peptides exhibited an antagonistic interaction, which could be attributed to their affinities for similar ligands, as deduced by peptide–ligand profiling. Moreover, both peptides inhibited biofilm formation, and they exhibited no resistance potential and low hemolytic activity. The peptides also possess the ability to permeate and disrupt the cell membranes of MDR P. aeruginosa and C. albicans. Therefore, recombinant actifensin and defensin-d2 exhibit broad-spectrum antimicrobial activity and have the potential to be used as therapy against MDR pathogens. View Full-Texten_US
dc.language.isoenen_US
dc.publisherUniversity of Nairobien_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectrecombinant; antimicrobial peptides; spinach defensin; actifensin; multidrug-resistanten_US
dc.titleMembrane Permeabilization and Antimicrobial Activity of Recombinant Defensin-d2 and Actifensin Against Multidrug-resistant Pseudomonas Aeruginosa and Candida Albicansen_US
dc.typeArticleen_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States